Intech Investment Management LLC Acquires 9,178 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Intech Investment Management LLC raised its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 62.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 23,806 shares of the biotechnology company’s stock after purchasing an additional 9,178 shares during the quarter. Intech Investment Management LLC’s holdings in Aldeyra Therapeutics were worth $119,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Raymond James Financial Inc. acquired a new position in shares of Aldeyra Therapeutics during the 4th quarter worth approximately $3,628,000. Jacobs Levy Equity Management Inc. boosted its position in Aldeyra Therapeutics by 163.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock worth $2,571,000 after purchasing an additional 295,864 shares during the period. Kennondale Capital Management LLC acquired a new position in shares of Aldeyra Therapeutics in the fourth quarter valued at $755,000. Barclays PLC raised its position in shares of Aldeyra Therapeutics by 280.1% in the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock valued at $353,000 after purchasing an additional 48,313 shares during the period. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Aldeyra Therapeutics during the 4th quarter worth about $234,000. 59.71% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a report on Monday, March 3rd.

Aldeyra Therapeutics Stock Down 0.6 %

Shares of NASDAQ ALDX opened at $6.26 on Friday. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. The stock’s fifty day moving average price is $6.06 and its two-hundred day moving average price is $5.52. Aldeyra Therapeutics, Inc has a one year low of $3.10 and a one year high of $7.20.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.30). On average, sell-side analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.